These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37166676)

  • 1. Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke.
    Zhai M; Cao S; Yang J; Cao X; Dong Z; Liu W; Fu Y; Guan Q; Wang Y; Liu H
    Neurol Ther; 2023 Aug; 12(4):1105-1118. PubMed ID: 37166676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial.
    Wang X; Robinson TG; Lee TH; Li Q; Arima H; Bath PM; Billot L; Broderick J; Demchuk AM; Donnan G; Kim JS; Lavados P; Lindley RI; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sharma VK; Thang NH; Wang JG; Woodward M; Anderson CS; Chalmers J;
    JAMA Neurol; 2017 Nov; 74(11):1328-1335. PubMed ID: 28973174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of Atherosclerotic Dyslipidemia with Long-Term Stroke Recurrence in Patients Undergoing Intravenous Thrombolysis for Acute Ischemic Stroke.
    Cheng Y; Wang Q; Niu G; Luo C
    Int J Gen Med; 2023; 16():1621-1629. PubMed ID: 37159580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Different Dosages of Alteplase in Atrial Fibrillation-Related Acute Ischemic Stroke After Intravenous Thrombolysis: A Nationwide, Multicenter, Prospective Cohort Study in Taiwan.
    Lin SF; Chen CF; Hu HH; Ho BL; Chen CH; Chan L; Lin HJ; Sun Y; Lin YY; Chen PL; Lin SK; Wei CY; Lin YT; Lee JT; Chao AC;
    J Am Heart Assoc; 2022 Feb; 11(3):e023032. PubMed ID: 35048714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants for a low dose of alteplase and its relationship to a lower intracerebral bleeding risk in acute ischemic stroke.
    Chen J; Li H; Lei H; Fang S; Yuan Q; Chen Y; Chen D; Chen R; Zhang Y; Wei J; Chen G; Chen Z; Liu N; Du HW
    Int J Med Sci; 2022; 19(12):1762-1769. PubMed ID: 36313231
    [No Abstract]   [Full Text] [Related]  

  • 6. Correlation Between Blood Glucose Variability and Early Therapeutic Effects After Intravenous Thrombolysis With Alteplase and Levels of Serum Inflammatory Factors in Patients With Acute Ischemic Stroke.
    Cai Y; Zhang H; Li Q; Zhang P
    Front Neurol; 2022; 13():806013. PubMed ID: 35273556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Medical Community Model on Intravenous Alteplase Door-to-Needle Times and Prognosis of Patients With Acute Ischemic Stroke.
    Li H; Xu D; Xu Y; Wei L
    Front Surg; 2022; 9():888015. PubMed ID: 35574548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive role of admission serum glucose, baseline NIHSS score, and fibrinogen on hemorrhagic transformation after intravenous thrombolysis with alteplase in acute ischemic stroke.
    Huang P; Yi XY
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9710-9720. PubMed ID: 37916334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose vs. standard-dose alteplase for Chinese patients with acute ischemic stroke: A propensity score analysis.
    Xu J; Chen X; Xie Y; Wang Y; Chen S; Dong Q; Dong Y; Fang K
    Front Neurol; 2023; 14():1120547. PubMed ID: 36895900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial.
    Chen G; Wang X; Robinson TG; Pikkemaat M; Lindley RI; Zhou S; Ping L; Liu W; Liu L; Chalmers J; Anderson CS;
    J Neurol Sci; 2018 Apr; 387():1-5. PubMed ID: 29571842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose vs. Standard-Dose Intravenous Alteplase in Bridging Therapy Among Patients With Acute Ischemic Stroke: Experience From a Stroke Center in Vietnam.
    Mai DT; Dao VP; Nguyen VC; Vu DL; Nguyen TD; Vuong XT; Bui QV; Phan HQ; Pham QT; Le HK; Tran AT; Nguyen QA; Dang PD; Nguyen H; Phan HT
    Front Neurol; 2021; 12():653820. PubMed ID: 33897607
    [No Abstract]   [Full Text] [Related]  

  • 12. Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial.
    Song L; Wang X; Robinson T; Lindley RI; Arima H; Lavados PM; Chen X; Chalmers J; Anderson CS
    Stroke Vasc Neurol; 2017 Jun; 2(2):53-58. PubMed ID: 28959492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of admission serum glucose on the clinical prognosis of patients with acute ischemic stroke receiving alteplase intravenous thrombolysis.
    Huang P; Yi X
    Int J Immunopathol Pharmacol; 2023; 37():3946320231204597. PubMed ID: 37771034
    [No Abstract]   [Full Text] [Related]  

  • 14. Rt-PA thrombolytic therapy in patients with acute posterior circulation stroke: A retrospective study.
    Hu Y; Zheng H; Chen X; Gao Z
    Med Int (Lond); 2022; 2(2):8. PubMed ID: 36699100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial.
    Zhou Z; Delcourt C; Xia C; Yoshimura S; Carcel C; Torii-Yoshimura T; You S; Malavera A; Chen X; Hackett ML; Woodward M; Chalmers J; Xu J; Robinson TG; Parsons MW; Demchuk AM; Lindley RI; Mair G; Wardlaw JM; Anderson CS
    Neurology; 2021 Mar; 96(11):e1512-e1526. PubMed ID: 33536271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study.
    Wang X; Song L; Yang J; Sun L; Moullaali TJ; Sandset EC; Delcourt C; Lindley RI; Robinson TG; Minhas JS; Arima H; Chalmers J; Kim JS; Sharma V; Wang JG; Pontes-Neto O; Lavados PM; Olavarría VV; Lee TH; Levi C; Martins SO; Thang NH; Anderson CS;
    Cerebrovasc Dis; 2019; 48(3-6):207-216. PubMed ID: 31812956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain Imaging Signs and Health-Related Quality of Life after Acute Ischemic Stroke: Analysis of ENCHANTED Alteplase Dose Arm.
    Chen X; Delcourt C; Sun L; Zhou Z; Yoshimura S; You S; Malavera A; Torii-Yoshimura T; Carcel C; Arima H; Hackett ML; Robinson T; Song L; Wang X; Lindley RI; Chalmers J; Anderson CS;
    Cerebrovasc Dis; 2020; 49(4):427-436. PubMed ID: 32702699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke.
    Tsivgoulis G; Katsanos AH; Christogiannis C; Faouzi B; Mavridis D; Dixit AK; Palaiodimou L; Khurana D; Petruzzellis M; Psychogios K; Macleod MJ; Ahmed N
    Ann Neurol; 2022 Sep; 92(3):349-357. PubMed ID: 35713213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of 1-Year Unfavorable Outcomes of Intravenous Alteplase Thrombolysis for Acute Ischemic Stroke.
    Zhai M; Yang J; Cao X; Li Y; Xu H; Wang Y
    Clin Appl Thromb Hemost; 2023; 29():10760296231187616. PubMed ID: 37461226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial.
    Song H; Wang Y; Ma Q; Feng W; Liu R; Lv X; Huang L; Li Y; Yang Y; Geng D; Zhu J; Wei Y; Chen H; Zhu R; Zhai Q; Guo J; Liu B; Zhao S; Wang Y;
    JAMA Netw Open; 2023 Jul; 6(7):e2325415. PubMed ID: 37490291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.